IM-101
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 23, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration to begin clinical trials of IM-101, a PreS1 recombinant fusion protein developed as a national Category 1 innovative drug for chronic hepatitis B.
(TipRanks)
- "IM-101 is designed to break immune tolerance and restore HBV-specific immune res
ponses, aiming for a functional cure by combining humoral and cellular mechanisms to neutralise viral particles, prevent reinfection and clear infected hepatocyt
es.
"
New trial • Hepatitis B
1 to 1
Of
1
Go to page
1